ÂÜÀòÂÒÂ×

Chinmaya is a global bio-pharma leader with a passion to bring innovative therapeutics to patients. For more than two decades, he has successfully assembled and led multi-functional teams that have consistently exceeded business objectives in dynamic situations by aligning people, objectives, priorities, and processes. He has effectively managed biotech start-ups, strategy, alliances, innovation, pre-clinical research, and commercial from early discovery to launch and in-line marketing across US, Europe, and Asia.

Most recently Chinmaya was the Entrepreneur-in-residence with Catena Biosciences, where he is appointed as a Director. As a Venture Partner with Social Impact Capital, he advised their early-stage biotech investments. Prior to that, he was a Founder CEO of CelluRx, a potential cell therapy spin-off of Saliogen Therapeutics. In 2019, Chinmaya joined the leadership team at Omega Therapeutics (a Flagship Pioneering Company) where he played a key role in defining the strategy, portfolio, innovation, and business development efforts from pre-Series A to IPO in 2021.

He also has expertise in business integration/acquisition, having led the US integration post-GSK Oncology acquisition and global commercial operations integration post-Alcon acquisition. He also has significant experience in leading high-impact enterprise-wide strategic projects at Novartis.

Chinmaya has profound business acumen in oncology/hematology therapeutics while leading major US launches in both hematology and solid tumors.

Chinmaya received MBAs from Warwick Business School, UK, and the Army Institute of Management Studies, India. He completed his undergraduate studies in Life Science with honors from Ravenshaw University, India.